Combined systemic (fluconazole) and topical (metronidazole + clotrimazole) therapy for a new approach to the treatment and prophylaxis of recurrent candidiasis.

摘要: Recurrent vulvovaginal candidiasis (RVVC) is an important pathological and infectious condition that can greatly impact a woman's health quality of life. Clinical epidemiological studies show different types therapies are able to eliminate the signs symptoms mycotic vaginitis in acute phase, but so far none these has proved significantly reduce risk long-term recurrence. In this review, based on available literature original data from preliminary in-vitro microbiological study compatibility between fluconazole, clotrimazole metronidazole new therapeutic approach RVVC discussed presented. The treatment proposed combined scheme using both systemic antimicrobial drug therapy with oral fluconazole 200 mg topical association 500 100 (vaginal ovules) adjuvant probiotic therapy. detail, at time diagnosis symptom we propose following scheme: day 1, 4, 11, 26, then 1 dose/month for 3 months end menstrual cycle; plus metronidazole/clotrimazole ovules 1/day 6 days first week, ovule/day week before cycle months; dose/day 10 starting second month cycle. This aims address recurrent infection aggressively outset by attempting not only treat symptoms, also prevent event countering many potential factors recurrence, such as intestinal Candida reservoir, biorhythm, formation biofilm, phenotype switching presence infections complicated C. non albicans or G. Vaginalis, without interfering, rather favoring restoration vaginal lactobacillus species. Future clinical will be useful confirm scheme.